Ibex Galen Prostate
AI-powered pathology software from Ibex Medical Analytics that assists pathologists in reviewing prostate biopsy slides, detecting and grading cancer, and reporting diagnostic findings in digital pathology workflows.
Why Abandoned
Ibex continues to list Galen Prostate within its pathology platform, and the FDA granted the product Breakthrough Device Designation in 2023. Public evidence supports ongoing commercial availability, though market access varies by jurisdiction.
🩺 Health Signals
No checks have been run on this tool yet.
📅 Timeline
Ibex Medical Analytics founded
Ibex raises $38 million Series B
FDA grants Breakthrough Device Designation
Ibex raises $55 million Series C
🔄 Alternatives to Ibex Galen Prostate
Bard / Gemini
🟢ActiveGoogle's AI assistant, originally Bard, rebranded to Gemini with multimodal capabilities.
Hugging Face
🟢ActiveThe GitHub of machine learning — hosting models, datasets, and AI applications.
OpenAI API
🟢ActiveAPI platform providing access to GPT models for developers to build AI applications.
🪦 Other dead Healthcare tools
Kheiron Mia
🟡Acquired / MergedMia is Kheiron Medical Technologies’ artificial intelligence platform for breast-screening mammography. It supports radiologists by analyzing mammograms and identifying cases that may warrant further review.
MaxQ AI ACCIPIO
🟠Possibly DeadACCIPIO was MaxQ AI's clinical AI platform for analyzing non-contrast head CT scans and prioritizing suspected intracranial hemorrhage cases for radiologist review. It was a triage aid, not a standalone diagnosis system.
Arterys Cardio AI
🟡Acquired / MergedCloud-based cardiac MRI analysis software that used machine learning to assist clinicians with image segmentation, ventricular measurements, and cardiac function assessment. Tempus acquired Arterys in 2022.
Zebra Medical Vision Imaging Analytics
🟡Acquired / MergedAI-based medical imaging analytics developed by Zebra Medical Vision to help identify findings in radiology scans. Nanox acquired Zebra in 2021 and incorporated its software into the Nanox.AI portfolio.
❓ Frequently Asked Questions
What is Ibex Galen Prostate?
Ibex Galen Prostate is AI-based clinical decision-support software for digital pathology. It analyzes digitized prostate biopsy slides to help pathologists identify cancer, grade findings, and produce diagnostic reports.
How does Ibex Galen Prostate help detect prostate cancer?
The software applies computational pathology models to whole-slide images from prostate biopsies. It highlights suspicious tissue and supplies case-level diagnostic information for review by a qualified pathologist; it is intended to support, not replace, professional judgment.
Is Ibex Galen Prostate FDA approved?
Ibex announced in June 2023 that the FDA granted Galen Prostate Breakthrough Device Designation. That designation is not the same as FDA marketing clearance or approval, and users should verify the latest regulatory status and authorized use directly with Ibex and relevant regulators.
Who makes Ibex Galen Prostate?
The product is developed by Ibex Medical Analytics, a computational pathology company founded by Joseph Mossel and Chaim Linhart in 2016.
Is Ibex Galen Prostate still available?
It appears active: Ibex continues to maintain a product page and describes Galen as part of its current pathology platform. Availability, integrations, and permitted clinical use depend on the country and applicable regulatory authorization.